Plain-English translation of NCT07613723 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
United Kingdom
Phase
Safety & dosing
Sponsor
Zelluna Immunotherapy AS
Enrollment target
~9 participants
Started
May 2026
Primary completion
December 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zelluna Immunotherapy
Zelluna Immunotherapy AS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.